{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:18Z","timestamp":1794047478477,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.284761","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:56:59Z","timestamp":1721876219000},"page":"4083-4088","source":"Crossref","is-referenced-by-count":1,"title":["A transgenic mouse model of Down syndrome acute lymphoblastic leukemia identifies targetable vulnerabilities"],"prefix":"10.3324","volume":"109","author":[{"given":"Jacob J.","family":"Junco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Rochette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Alozie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raushan","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maci","family":"Terrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Zorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Sumazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Dettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid T.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford C.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Martinez-Moczygemba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"70187","doi-asserted-by":"crossref","unstructured":"Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. Lancet. 2000; 355(9199):165-169.","DOI":"10.1016\/S0140-6736(99)05264-2"},{"key":"70188","doi-asserted-by":"crossref","unstructured":"Buitenkamp TD, Izraeli S, Zimmermann M. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014; 123(1):70-77.","DOI":"10.1182\/blood-2013-06-509463"},{"key":"70189","doi-asserted-by":"crossref","unstructured":"Hertzberg L, Vendramini E, Ganmore I. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010; 115(5):1006-1017.","DOI":"10.1182\/blood-2009-08-235408"},{"key":"70190","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Collins-Underwood JR, Phillips LA. Rearrangement of CRLF2 in B-progenitor- and Down syndromeassociated acute lymphoblastic leukemia. NatGenet. 2009; 41(11):1243-1246.","DOI":"10.1038\/ng.469"},{"key":"70191","doi-asserted-by":"crossref","unstructured":"Koschut D, Ray D, Li Z. RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. Oncogene. 2021; 40(4):746-762.","DOI":"10.1038\/s41388-020-01567-7"},{"key":"70192","doi-asserted-by":"crossref","unstructured":"Li Z, Chang TC, Junco JJ. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023; 142(2):172-184.","DOI":"10.1182\/blood.2023019765"},{"key":"70193","doi-asserted-by":"crossref","unstructured":"Li Z, Yu T, Morishima M. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum Mol Genet. 2007; 16(11):1359-1366.","DOI":"10.1093\/hmg\/ddm086"},{"key":"70194","doi-asserted-by":"crossref","unstructured":"Brady SW, Roberts KG, Gu Z. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022; 54(9):1376-1389.","DOI":"10.1038\/s41588-022-01159-z"},{"key":"70195","doi-asserted-by":"crossref","unstructured":"Sullivan KD, Lewis HC, Hill AA. Trisomy 21 consistently activates the interferon response. Elife. 2016; 5:e16220.","DOI":"10.7554\/eLife.16220"},{"key":"70196","doi-asserted-by":"crossref","unstructured":"Zaliova M, Stuchly J, Winkowska L. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica. 2019; 104(7):1396-1406.","DOI":"10.3324\/haematol.2018.204974"},{"key":"70197","doi-asserted-by":"crossref","unstructured":"Schraw JM, Junco JJ, Brown AL, Scheurer ME, Rabin KR, Lupo PJ. Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia. EBioMedicine. 2019; 48:49-57.","DOI":"10.1016\/j.ebiom.2019.09.033"},{"key":"70198","doi-asserted-by":"crossref","unstructured":"Carey-Smith SL, Simad MH, Panchal K. Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia. Haematologica. 2024; 109(7):2309-2315.","DOI":"10.3324\/haematol.2023.284271"},{"key":"70199","doi-asserted-by":"crossref","unstructured":"Lane AA, Chapuy B, Lin CY. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014; 46(6):618-623.","DOI":"10.1038\/ng.2949"},{"key":"70200","doi-asserted-by":"crossref","unstructured":"Galbraith MD, Rachubinski AL, Smith KP. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Sci Adv. 2023; 9(26)","DOI":"10.1126\/sciadv.adg6218"},{"key":"70201","doi-asserted-by":"crossref","unstructured":"Zwaan CM, Kaspers GJ, Pieters R. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002; 99(1):245-251.","DOI":"10.1182\/blood.V99.1.245"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284761\/77321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284761\/77844","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11701\/77321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:58Z","timestamp":1794046018000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284761","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}